Genetic testing is undergoing rapid growth.
Image has been resized. Courtesy of emedgene.
Emedgene, a company that offers clinical genetic interpretation and diagnostics, today announced a $6 million funding round to scale genomics-based care with artificial intelligence (AI).
Its self-titled automated genetic interpretation platform is used to discover causative genetic variants and supporting evidence for exome, genome and panels in many different applications, including rare disease identification, healthy population screening and pharmacogenomics.
“Genetic medicine will inevitably become the medical standard of care, if we can remove the hurdles to wider adoption,” said Einat Metzer, CEO of Emedgene. “Emedgene does just that, with AI that can surface scientific knowledge in clinical settings, so that every patient has access to the best possible care,” she added.
Emedgene uses an AI engine that was trained with millions of data points from patient cases, databases and recent genomics publications to perform genomic research. The platform interprets genetic tests automatically, helping improve the workflow of geneticists and providing more accurate results.
Currently, Emedgene is being used by many health organizations, including Israel’s MoH 100K Genome Project.
The funding was led by Olive Tree Ventures, a company focused on investing in businesses that use innovations to improve the lives of others.
“Genetic testing and discovery are clearly undergoing rapid growth, and Emedgene has a game-changing solution rooted in a combination of technology and science,” said Amir Lahat, general partner at Olive Tree Ventures.
Emedgene plans on using the funds to expand its sales in the U.S.
Get the best insights in healthcare analytics directly to your inbox.